Bloodstream Infection Testing Market Forecast 2023 - 2031

By Product Type :

The product type of segmentation is categorized into consumables, instruments, and software. In 2022, consumables segment accounted for the highest market share in the bloodstream infection testing market. Consumable bloodstream infection testing refers to the use of disposable materials and reagents to detect bloodstream infections. These consumables are used in a variety of bloodstream infection testing methods, including blood culture, nucleic acid testing (NAT), and mass spectrometry. Consumables are used in every bloodstream infection test, such as blood culture bottles, media, and reagents. Additionally, consumables are relatively inexpensive and have a short shelf life, which drives their demand across the globe.

Moreover, the instruments are expected to hold the highest CAGR over the forecast period. Instruments products in bloodstream infection testing are devices that are used to detect and identify bacteria and fungi in the bloodstream. These devices are becoming increasingly popular because they offer several advantages over traditional methods of bloodstream infection testing, such as blood culture. Advancement in instruments such as automated blood culture systems and molecular diagnostics instruments is helping to reduce the turnaround time for bloodstream infection testing. The superior performance characteristics of the products are creating lucrative growth opportunities for instruments in bloodstream infection testing over the forecast period.

By Technology :

The technology segment is categorized into conventional, PCR methods, nucleic acid testing, mass spectroscopy, and POC testing. In 2022, the conventional segment accounted for the highest market share in the bloodstream infection testing market. Conventional bloodstream infection (BSI) testing is the traditional method for detecting bacteria and fungi in the bloodstream. It involves collecting a blood sample and incubating it in a nutrient-rich broth for several days. If bacteria or fungi are present in the blood sample, they will grow in the broth and can be detected by a laboratory technician. The growing awareness of the importance of early detection and treatment of bloodstream infections is driving the demand for conventional bloodstream infection testing across the globe.

Moreover, the POC testing is expected to hold the highest CAGR over the forecast period. Point-of-care (POC) testing in bloodstream infection testing refers to the use of small, portable devices to detect bloodstream infections at the patient's bedside. POC testing devices can be used to detect bacteria, fungi, and viruses in the bloodstream. POC tests produce results in minutes or hours, compared to days for traditional laboratory-based tests. This can lead to earlier diagnosis and treatment of bloodstream infections, which can improve patient outcomes. The faster turnaround time of POC testing is creating lucrative growth opportunities for POC testing in bloodstream infection testing over the forecast period.

By End User :

The end user segment is categorized into hospitals, diagnostic centers, research institutes, and others. In 2022, the hospitals segment accounted for the highest market share of 43.10% in the application segment. Hospitals are the primary setting where bloodstream infections are diagnosed and treated. Hospitals have the necessary infrastructure and resources to perform a variety of bloodstream infection tests, including blood culture, nucleic acid testing (NAT), and mass spectrometry. The increasing number of hospitals across the developing economies is driving the demand for bloodstream infection testing from the healthcare sector across the globe. For instance, according to the report by Investment Information and Credit Rating Agency, in August 2023, the hospital sector is expecting a robust revenue growth of 8-10% in FY24, with an operating profit margin of 22-23%. Thus, the growing demand for bloodstream infection testing from the healthcare sector is driving the market growth.

Moreover, the diagnostic centers are expected to hold the highest CAGR over the forecast period. The demand for bloodstream infection testing is growing from diagnostic centers due to the increasing demand for outpatient bloodstream infection testing. Diagnostic centers offer patients a convenient and affordable way to get tested for bloodstream infections. Growing government initiatives for the development of diagnostic centers is fueling the market growth. For instance, according to the report by the Government of United Kingdom in May 2023, The government has committed USD 2.81 billion to launch up to 160 community diagnostic centers (CDCs) by March 2025. Thus, the growing number of diagnostic centers is expected to create lucrative growth opportunities for segment growth across the globe.

Get More Information

Download Sample Report

By Region :

The regional segment includes North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 38.25% valued at USD 1,255.99 Million in 2022 and USD 1,307.85 Million in 2023, it is expected to reach USD 1,864.86 Million in 2031. In North America, the U.S. accounted for the highest market share of 63.10% in the base year 2022. The significant growth in bloodstream infections across the North America region is driving the market growth across the region. For instance, According to the Centers for Disease Control and Prevention (CDC) in September 2021, at least 1.7 million adults in the U.S. develop sepsis each year which leads to 270,000 every year. Furthermore, according to the report by the National Institute of Health in November 2022, An estimated 250,000 bloodstream infections occur annually, and most are related to the presence of intravascular devices. In the United States, the CLABSI rate in intensive care units (ICU) is estimated to be 0.8 per 1000 central line days. Thus, the growing prevalence of blood infections in the North America region is driving demand for bloodstream infection testing and driving the market growth.

Furthermore, the Asia Pacific region is expected to witness significant growth over the forecast period, growing at a CAGR of 4.9% during 2023-2031. The significant growth in healthcare infrastructure across the region across the region is increasing demand for bloodstream infection testing. For instance, according to a report by the National Institute of Health in May 2023, China's healthcare budget is gradually increasing. The ratio of health expenditures to GDP in 2021 was 6.5%. It was only 4.3% to 5.2% during the period from 2000 to 2010. The total national health expenditure in 2021 will be USD 1184.9 billion. Thus, the significant growth in healthcare infrastructure is expected to create opportunities for growth in the bloodstream infection testing market over the forecast period.